![Dr Jennifer Snaith](https://api.research.unsw.edu.au/sites/default/files/images/profile/Jennifer%2BSnaith%2BEndocrinologist%2BSydney%2B2.jpg)
Dr Jennifer Snaith
FRACP, MBBS (Hons), BMedSci
Dr Jennifer Snaith is an Endocrinologist and Research Fellow based at the Garvan Institute of Medical Research. Her career mission is to improve the lives of people living with type 1 diabetes through clinical service, advocacy and innovative research.
She is a Staff Specialist Endocrinologist at St Vincent's Hospital, and established with her team (Marhava/Lum/Higgins), the Diabetes in Youth (DIY) service in 2021. Her research activities are clinically based and relate to type 1 diabetes, insulin resistance, adjunctive therapies and cardiometabolic risk.
Prof Jerry Greenfield and Dr Snaith established the Garvan Institute 'Australian Type 1 Diabetes Mellitus Adjuncts Group' (AUS-TAG). The AUS-TAG mission is to prolong the life of Australians living with type 1 diabetes by preventing cardiovascular disease through novel repurposing of cardioprotective medications. AUS-TAG specialise in the conduct of clinical trials in type 1 diabetes. These studies include detailed mechanistic studies, to phenotype metabolic health in type 1 diabetes, and the physiological impacts of adjunctive therapies on cardiometabolic health in type 1 diabetes.
During her PhD candidature (primary supervisor Greenfield) Dr Snaith conducted the INTIMET study (INsulin resistance in type 1 diabetes managed with METformin) and was a recipient of the National Health and Medical Research Council (NHMRC) Post Graduate Scholarship, and Diabetes Australia top up scholarship. The INTIMET study was a placebo controlled randomised controlled clinical examining the impact of metformin on hepatic and muscle insulin resistance, assessed using hyperinsulinaemic euglycaemic clamps.
The RESET1 study (Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes) is the second clinical trial from the AUS-TAG group. Snaith was awarded the Diabetes Australia Coghlan Award for Emerging Researchers, and the Rebecca Davies Fellowship from JDRF Australia to conduct this randomised placebo controlled clinical trial to examine the effect of semaglutide on cardiovascular risk in adults with type 1 diabetes. Trial registration: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386649&isReview=true
The TIRTLE study (Tirzepatide in Type 1 Diabetes: Cardiometabolic Effects) is a tirzepatide in type 1 diabetes placebo controlled trial. Trial registration: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386985&isReview=true
- Publications
- Awards
- Grants
- Research Activities
- Engagement
- Teaching and Supervision
- Media
2024 - Australian Diabetes Society Lindsey Baudinet Rising Star Award in Type 1 Diabetes Research
2023 - Diabetes Australia Coghlan Award: for project Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)
2022 - JDRF Rebecca Davies Fellowship
2022 - Australian Diabetes Society Clinical Young Investigator's Award
2021 - UNSW ARC Postgraduate Council Research Student Award
2020 - UNSW Visualise Your Thesis (Runner Up)
2020 - NHMRC Post Graduate Scholarship
2020 - NHMRC/Diabetes Australia co-funding award
2019 - UNSW University Post Graduate Award
2018 - Joan Waugh Scholarship for academic excellence and leadership potential
2018 - Westmead Association Tracey Robinson Registrar Award for Excellence in Teaching
2017 - Westmead Association Advanced Trainee of the Year
2015 - Westmead Association Tracey Robinson Registrar Award for Excellence in Teaching
2007 - University of Sydney Exchange Scholarship
2005 - Medical Science Scholarship